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Summary 
A prominent characteristic of human immunodeficiency virus type 1 (HIV-1) is  its high 
genetic variability, which generates diversity of the virus and often causes a serious problem of the 
emergence of drug-resistant mutants. Subtype B HIV-1 is  dominant in advanced countries, and the 
mortality rate due to subtype B HIV-1 has been decreased during the past decade. In contrast, the number 
of patients with non-subtype B viruses is still increasing in developing countries. One of the reasons for 
the prevalence of non-subtype B viruses is  lack of information about the biological and therapeutic 
differences between subtype B and non-subtype B viruses. M36I is  the most frequently observed 
polymorphism in non-subtype B HIV-1 proteases. However, since the 36th residue is located at a 
non-active site of the protease and has no direct interaction with any ligands, the structural role of M36I 
remains unclear. In this study, we performed molecular dynamics (MD) simulations of M36I protease in 
complex with nelfinavir and revealed the influence of the M36I mutation. The results  show that M36I 
regulates the size of the binding cavity of the protease. The reason for the rare emergence of D30N 
variants in non-subtype B HIV-1 proteases was also clarified from our computational analysis. 
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Introduction 
Human immunodeficiency virus type 1 (HIV-1) is  one of the most hazardous viruses for 
humans. HIV-1 has a high genetic variability and has been classified into three groups: M, N, and O 
groups. Viruses in group M are further subdivided into subtypes, sub-subtypes, and circulating 
recombinant forms (CRFs). The subtype B virus is  commonly found in HIV-1-infected patients in North 
America, Europe, and Japan. Some anti-HIV-1 drugs that target viral proteins (reverse transcriptase, 
aspartic protease, and fusion proteins) have been clinically used and have lowered the death rate due to 
acquired immune defic iency syndrome (AIDS) in advanced countries during the past decade. In contrast, 
developing countries are suffering from a growing ep idemic of non-subtype B viruses. The number of 
patients infected with HIV-1 is still increasing in developing countries.1 
HIV-1 proliferates under the assistance of its  own aspartic protease, so-called HIV-1 protease 
(HIV-1 PR), in its life cycle.2 HIV-1 PR is an enzyme composed of two identical polypeptides, each of 
which consists of 99 amino acid residues (Fig. 1a), and has a function to process the viral Gag and 
Gag-Pol polyprotein precursors. Because this processing is  essential for viral maturation, inhibition of the 
PR function leads to incomplete viral rep lication and prevents the transfer to other human cells.3 
Therefore, HIV-1 PR is an attractive target for anti-HIV-1 drugs. Nine PR inhibitors (PIs) have been 
approved by the Food and Drug Administration (FDA).4-12 Nevertheless, the currently available PIs were 
developed and tested only against subtype B PRs. Some studies have shown that non-subtype B viruses 
show different responses than the responses of subtype B virus to those PIs.13-18 Ariyoshi et al. reported 
that the patterns of emergence of resistant mutations against nelfinavir (NFV, Fig. 1b) differed between 
subtype B and CRF01_AE HIV-1.17 D30N predominantly appears in patients who are infected with 
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subtype B HIV-1, and treatment with NFV has failed. D30N specifically confers resistance against 
NFV.19,20 In contrast, N88S predominantly appears in patients with CRF01_AE HIV-1. D30N is not 
found in patients with CRF01_AE HIV-1. D30N has also rarely been found in patients with other 
non-subtype B HIV-1.21-24 However, there have been few studies on the susceptibility of non-subtype B 
viruses to the presently availab le PIs, and a standard protocol of chemotherapy for non-subtype B viruses 
has not yet been established.25 
Non-subtype B HIV-1 PRs have natural polymorphisms. Among those polymorphisms, M36I 
is  the most frequently observed in patients with non-subtype B HIV-1.24,26,27 M36I is  known to be related 
to resistance against some FDA-approved PIs: NFV, ind inavir, ritonavir, and atazanavir.20 Therefore, 
M36I is a key mutation to understand the difference between subtype B and non-subtype B HIV-1 PRs. 
Nevertheless, the structural role of the non-active s ite mutation M36I remains unclear. This is because the 
36th residue of PR is not located at the active site of PR and has no direct interaction with any substrates 
or any PIs.  
In this study, we investigated the structural role of M36I of PR in the binding of PR with 
NFV through computational simulations. We also examined the structural role of M36V in order to 
compare the effect of the side chain at the 36th residue. Some previous computational simulations have 
revealed structural ro les of non-active site mutations of HIV-1 PR.28-34 Our simulations indicated that the 
mutations at the 36th res idues influence the volume of the bind ing cavity of the active site of PR. The 
influence on the volume alters the interaction between D30 of PR and NFV. We also investigated the 
relationship between D30N and the mutation at the 36th residue of PR. Our results  revealed that a 
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combination of D30N and the mutation at the 36th residue induces the formation of hydrogen bonds 
between N30 of PR and NFV, which are not observed in PR with a single D30N mutation in complex 
with NFV. Our simulations suggest that M36I, despite the fact that it is  a mutation at a non-active site, 
regulates the binding of ligands with PR. These findings will be helpful for developing more effective PIs 
against non-subtype B HIV-1.  
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Results 
Hydrogen bond networks. We performed MD simulations of six subtype B HIV-1 PRs in complex with 
NFV: wild-type (WT) PR, M36I PR, M36V PR, D30N PR, D30N/M36I PR, and D30N/M36V PR 
(labeled as B(WT), B(M36I), B(M36V), B(D30N), B(D30N/M36I), and B(D30N/M36V), respectively). 
First, in order to clarify the structural role of the mutation at the 36th residue, we examined direct or 
one-water-molecule-mediated hydrogen bonds between each PR and NFV (Table 1, Supporting Material 
Table S1). According to the X-ray structure of HIV-1 PR bound to NFV,35 NFV has direct and 
one-water-molecule-mediated hydrogen bonds with D25/D25’, I50/I50’, D29’, and D30 (Supporting 
Material Fig. S1). In all of the six models, the side chains of D25 and D25’ directly interacted with the 
central hydroxyl group of NFV (O3 in F ig. 1b).  All of models also have one-water-molecule-mediated 
hydrogen bonds of NFV with I50/I50’ and with D29’. Different hydrogen bonds are observed between the 
30th residue and the phenol group of NFV. In B(WT) and B(M36V), either the main chain or the s ide 
chain of D30 interacts with NFV through hydrogen bonds (Fig. 2). In B(M36I), only the side chain of 
D30 forms a hydrogen bond with NFV. In contrast, B(D30N) has no hydrogen bond with NFV. 
B(D30N/M36I) and B(D30N/M36V) show a different feature from that of B(D30N). They have direct 
hydrogen bonds between the main chain of N30 and NFV. 
Change in conformation of PR. Next, we investigated the d ifference in the average structure of each PR 
from that of B(WT). The average structure of each PR was generated from 1000 snapshot structures 
during the last 1.0 ns MD simulations. In order to make a comparison between each PR and of B(WT), 
we superimposed the average structure of each PR onto that of B(WT) using the coordinates of N, Cα, 
and C atoms. Since non-active site residues are more flexib le than active site residues and the structure of 
non-active site residues is  largely influenced by random atom motions in MD simulation (Supporting 
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Material Fig. S2), we focused on conformational change of the active site residues. Fig. 3 shows that the 
displacements of most of the active s ite residues are small. Detailed values are shown in Supporting 
Material Fig. S3. Exceptionally, a large conformational change (RMSD=1.5Å) is observed at D29 in 
B(D30N/M36I). In the other PRs, D29 is shifted about 0.7 Å. D30 is noticeably displaced by 0.8 Å in 
only B(D30N), while displacement of the 30th residues is less than 0.5 Å in the other PRs. At a flap 
region and around 80’s loops, slight conformational changes are also observed. The flap and 80’s loop 
consist of the 47th to 50th residues and of the 79th to 81st residues, respectively. Although HIV-1 PR is a 
homodimer, the asymmetric displacements are observed. The displacement in NFV was also examined 
(Supporting Material Fig. S4).  Conformational changes in the benzamide group and the S-phenyl group 
(C6H6-S-) are observed. B(D30N) and B(D30N/M36I) show larger displacement than that of the other 
models. In contrast, the tert-butylcarboxamide mo iety and the dodecahydroisoquinoline ring hardly 
change their locations in each model. The displacements of NFV are also asymmetric and correlate with 
the displacements of PR. The residues near the benzamide group of NFV, such as the 29th and 30th 
residues, show large displacement. On the other hand, the residues near the tert-butylcarboxamide moiety 
or the dodecahydroisoquinoline ring of NFV show small displacements. The asymmetric displacements 
observed in HIV-1 PR will be due to the structural collision with NFV. 
Furthermore, we examined the effect of the mutation at the 36th residue on volume of the 
active site (Table 2). M36I reduces the volume of the active site, whereas both D30N and D30N/M36I 
increase it. M36V and D30N/M36V have almost no effect on the volume.  
 
Binding energy calculations. Binding energy between each PR and NFV is presented in Table 3. A 
single M36I or M36V mutation has almost no effect on the binding affinity with NFV, although the 
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binding energy calculations have large standard deviations. In contrast, D30N and D30N/M36I mutations 
reduce the binding energies with NFV. Oppositely, D30N/M36V increases the affinity. Clemente et al. 
reported the IC50 values of B(WT), B(D30N), B(M36I), and B(D30N/M36I),36 in which M36I was 
suggested to improve the binding affinity with NFV, and showed that D30N/M36I conferred resistance 
against NFV. Our results  are compatible with those experimental results.  
 We additionally analyzed the contribution of each residue to the binding of NFV (Supporting 
Material Fig. S5). In B(M36I), B(M36V), and B(D30N/M36V), the respective residues except D25/D25’ 
have contributions similar to those in B(WT). The contribution of D25/D25’ depends on their protonation 
states. In contrast, B(D30N) reduces the binding energy between the 30th residue and NFV. 
B(D30N/M36I) lowers the interaction between D29 and NFV.  
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Discussion 
In this study, we performed MD simulations of HIV-1 PRs in complex with NFV for the 
purpose of clarifying (1) the structural role of the non-active site mutation M36I and (2) the relationship 
between D30N and M36I mutations. M36V was also examined in order to analyze the effect of the s ide 
chain of the 36th residue. 
Non-subtype B HIV-1 is  still pandemic in the world.1 Nevertheless, a standard protocol of 
chemotherapy for non-subtype B viruses has not yet been established,25 and little is  known about the 
difference between susceptib ilities of non-subtype B viruses and subtype B virus to clinically available 
drugs.13-18  M36I is the most frequently observed polymorphism among non-subtype B HIV-1 PRs.24,26,27 
Therefore, M36I is  a key mutation to clarify the reason why the efficacy of PIs varies among subtypes. 
Some studies have indicated that M36I is related to the resistance against NFV and other FDA-approved 
PIs  by complementing the effects of other res istant mutations.17,20,34,36 For example, M36I has been shown 
to contribute to an increase in the emergence rate of the NFV-resistant mutation N88S.17,34 It has also 
been reported that a single M36I mutation does not confer resistance against FDA-approved PIs.36 The 
structural role of M36I is , however, not clear because the 36th residue of PR is located at a non-active site 
of HIV-1 PR. According to the results of the present simulations, a single M36I mutation reduces the 
volume of the binding cavity of subtype B HIV-1 PR. Energetically, M36I PR slightly increases the 
binding affinity with NFV, compared with WT PR. This result is compatible with an experimental 
finding.36 A single M36V mutation also reduces the volume of the cavity, although the effect of M36V on 
the cavity volume is not as great as that of M36I. When we carried out the additional 2.0ns MD 
simulation of each model, the reduction of the volume of the active site of M36I PR and that of M36V PR 
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were also observed (Supporting Material Table S2). Therefore, the side chain of the 36th residue will 
indeed influence the shape of the active site of PR, despite its  location. 
In order to reveal the mechanism by which the non-active site mutation M36I regulates the 
volume of the active site of PR, we additionally calculated the interaction energy between each residue of 
PR and the 36th residue. The energy calculations suggest that the 36th residue mainly interacts with 
I15/I15’, Q18/Q18’, K20/K20’, L33/L33’, and V77/V77’ (Supporting Material Fig. S6). Among these 
residues, L33/L33’ and V77/V77’ are located near active site residues (Fig. 4). V77/V77’ is  close to the 
80’s loop, which consists of the residues from P79/P79’ to P81/P81’. L33/L33’ is  in the vicinity of 
T31/T31’. Interestingly, mutations at L33 and V77 (L33F and V77I) are also related to the resistance 
against some PIs.20 These mutations would play a role similar to that of M36I. We speculate that the 
slight inward shifts  of L33/L33’ and V77/V77’ due to the mutation M36I trigger the reduction in volume 
of the cavity of PR. In order to confirm this speculation, we further examined the shift of each residue and 
extracted the shift only toward the center of the active site (F ig. 5, Supporting Materials Fig. S7-S9). The 
results show that M36I causes a shrinkage of the active site around P79 and around T31’. The 31st 
residue T31/T31’ creates stable hydrogen bond networks with D29, T74, and N88 or with D29’, T74’, 
and N88’ (Supporting Material Table S3).28,34 Therefore, M36I also indirectly influences the 
conformations around D29/D29’. A28’, D29’, D30’, and T31’ in one monomer are all displaced inward. 
In contrast, A28 and D29 show outward positional shifts , while the residues around L33 in the other 
monomer move inward. It is  notable that these residues rotate on D30. M36I hardly shrinks or expands 
the cavity at D30. However, D30 shifts  toward the α-helix region (R87-I93) in B(M36I) (Supporting 
Material Fig. S10). Although this displacement is very slight (0.4Å), the shift enlarges the distance from 
the main chain of D30 to the m-phenol group of NFV, and it also shortens the distance from the side 
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chain of D30 to NFV (Fig. 2). Therefore, M36I changes the interaction between D30 and NFV. D30 is an 
important residue for binding with NFV.28,34,35 B(M36I) has a hydrogen bond of the m-phenol group of 
NFV only with the side chain of D30 unlike B(WT). B(WT) forms hydrogen bonds of the m-phenol 
group of NFV with either the main chain or the s ide chain of D30. These results  show that the non-active 
site mutation M36I influence the shape of the active site of PR by the following mechanism. M36I 
mutation shifts L33/L33’ and V77/V77’ inward. Subsequently, those shifts cause change in 
conformations at the active site, especially around T31/T31’ and P79/P79’.  
It is also informative to investigate the relationship between D30N and M36I. As stated in the 
introduction section, most of the non-subtype B HIV-1 PRs carry M36I as a polymorphism.24,26,27 In 
contrast, D30N rarely appears in non-subtype B HIV-1 PRs.21-24 This rare emergence of D30N in 
non-subtype B PRs has been assumed to be due to the low viral replication ability of D30N mutants in 
non-subtype B viruses,22,37 because L89M, which is  a polymorphism of some non-subtype B PRs, and 
D30N decrease the replication ability.22,37 On the other hand, our simulations provide a novel insight 
about the relationship between D30N and M36I. It should be noted that B(D30N/M36I) forms a hydrogen 
bond between the main chain of N30 and NFV (Fig. 2), which is  not seen in B(D30N). M36I enforces the 
interaction between N30 and NFV in D30N mutant PR. A clear difference is observed at D29 among 
B(WT), B(M36I), B(D30N), and B(D30N/M36I) (Fig. 5). D29 in B(D30N/M36I) shows a large outward 
positional shift from that of B(WT). The shift of B(D30N/M36I) is  two-times larger than that of B(M36I) 
and B(D30N). Binding energy calculations show that D30N/M36I lowers the binding affinity of NFV 
with subtype B PR (Table 3) and greatly reduces the interaction between D29 and NFV. D30N/M36I 
mutant of subtype B PR was reported to confer resistance against NFV.36 This energetical result is 
compatib le with experimental findings.36 These results  suggest that the res istance mechanism due to 
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D30N/M36I is different from that of D30N. D30N causes resistance against NFV because of the loss of 
hydrogen bonds between N30 and NFV.28,34 On the other hand, D30N/M36I confers resistance against 
NFV due to the large change in conformation at D29. NFV still interacts with N30 in B(D30N/M36I). It 
is  known that D30N is not observed in CRF01_AE PR.17 As we previously reported,34 this observation is 
explained from the finding that the affinity of CRF01_AE D30N PR with NFV is similar to that of 
CRF01_AE reference PR. CRF01_AE D30N PR has stronger interaction with NFV than does subtype B 
D30N PR. CRF01_AE D30N PR has one-water-mo lecule-mediated hydrogen bonds between NFV and 
N30, whereas subtype B D30N PR forms no hydrogen bond between them. M36I enforces the interaction 
between N30 and NFV, and polymorphisms other than M36I will release the distortion at D29. NFV will 
be able to maintain its  efficacy against D30N mutant PR in non-subtype B viruses. Therefore, D30N 
mutation is  rarely observed in non-subtype B HIV-1 PRs. 
In this study, we performed MD simulations of six HIV-1 PRs in complex with NFV and 
clarify the structural ro le of the non-active site mutation M36I. M36I influences the shape of the active 
site of PR in spite of its  location. The change in conformations at the active s ite is caused by the alteration 
of interaction of the 36th residue with L33 and V77. We also examined the relationship between D30N 
and M36I. A combination of D30N and M36I enforces the interaction between N30 and NFV, causing 
distortion on the conformation around D29. D30N/M36I shows a different mechanism of resistance 
against NFV from that of D30N. M36I is the most frequently observed mutation in non-subtype B PRs. 
Therefore, M36I is  a key mutation to understand the differences between subtype B and non-subtype B 
PRs. The findings of this study provide valuable information for developing the drugs that are more 
effective for non-subtype B PRs. Furthermore, accumulation of information on structural roles of key 
residues of PR will enable us to predict the effectiveness of PIs against non-subtype B viruses as well as 
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against subtype B ones. 
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Materials and Methods 
Molecular dynamics (MD) simulation. We performed minimizations and MD simulations in a manner 
similar to that described elsewhere.34 Minimizations and MD simulations were carried out using the 
Sander module of the AMBER8 package.38 The AMBER ff03 force field39 was used as the parameters for 
proteins, ions, and water molecules. Our originally developed torsion parameters for the benzamide 
moiety in NFV, CA-CA-C –N and CA-CA-C –O, were applied.34 The general AMBER force field40 was 
used as other parameters for NFV. RESP charges for NFV were determined on the basis of data obtained 
from quantum chemical calculations.34 
We performed simulations of six proteases (PRs) in complex with NFV: wild-type (WT) PR, 
M36I PR, M36V PR, D30N PR, D30N/M36I PR, and D30N/M36V PR of subtype B HIV-1 (labeled as 
B(WT), B(M36I), B(M36V), B(D30N), B(D30N/M36I), and B(D30N/M36V), respectively). B(M36V) 
and B(D30N/M36V) were examined in order to analyze the effect of the side chain of the 36th residue 
much clearly. We used HXB2 as the WT sequence of subtype B HIV-1. Each initial structure for the PR 
in complex with NFV was modeled from the atom coordinates of an X-ray crystal structure (PDB code: 
1OHR35) and the respective mutations were introduced using the LEaP module. First, we obtained the 
PDB file of the PR bound to NFV from Protein Data Bank (http ://www.pdb.org/). Second, we edited the 
PDB file to change the residue names of the mutated residues and to delete the information on the 
coordinates of the side chain atoms of the mutated residues. Third, the coordinates of the side chain atoms 
of the mutated residues were automatically generated by LEaP module. Fourth, each model was placed in 
a rectangular box filled with about 8000 TIP3P water molecules,41 with all of the crystal water molecules 
remaining. The cutoff distance for the long-range electrostatic and the van der Waals energy terms was 
set to 12.0 Å. The expansion and shrinkage of all covalent bonds connecting to a hydrogen atom were 
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constrained using the SHAKE algorithm.42 Periodic boundary conditions were applied to avoid the edge 
effect in all calculations. Energy minimization was achieved in three steps. First, movement was allowed 
only for water molecules and ions. Next, the ligand and the mutated residues were allowed to move in 
addition to the water molecules and ions. In this step, steric collis ions of the automatically generated 
residues were minimized and favorable configurations of the side chains of the mutated residues were 
obtained. Finally, all atoms were permitted to move freely. In each step, energy minimization was 
executed by the steepest descent method for the first 10000 cycles and the conjugated gradient method for 
the subsequent 10000 cycles. After a 0.1 ns heating calculation until 310 K using the NVT ensemble, a 
3.0 ns equilibrating calculation was executed at 1 atm and at 310 K using the NPT ensemble, with an 
integration time step of 2.0 fs. In the present calculations, the MD simulations showed no large 
fluctuations after about 2.0 ns equilibrating calculation (Supporting Materials Fig. S11, S12). Hence, 
atom coordinates were collected at intervals of 1.0 ps for the last 1.0 ns to analyze the structure in detail. 
Furthermore, we performed the additional 2.0 ns simulation for each model and confirmed equilibrium of 
each simulation (Supporting Material F ig. S13). 
Protonation states of the catalytic aspartic acids D25 and D25’ vary depending on the binding 
ligands or PRs.43 Hence, appropriate protonation states of the catalytic aspartic acids should be 
determined for each model. Since NFV mimics a transition state of catalytic reaction by HIV-1 PR, we 
considered two kinds of protonation states.44-46 One complex represented a combination of protonated 
D25 / unprotonated D25’ states, and the other represented the opposite combination. In order to determine 
the protonation states when NFV is bound to each PR, the free energies of two kinds of complexes were 
compared using calculation data obtained during the 2.0-3.0 ns MD s imulations (Supporting Material 
Table S4). The free energies were calculated on the basis of the MM/PBSA method.47,48 We used the 
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same parameter set for electrostatic and van der Waals energy terms as that used in the MD s imulations, 
and no cutoff was applied for the calculation. Since the dielectric constants for the interio r of proteins is 
considered to be in the range of 2 to 4, the interio r dielectric constant was set to 2.0.49 The outer dielectric 
constant was set to 80.0. The pbsa program was used to solve the Poisson-Boltzmman (PB) equation. 
B(D30N), B(M36I), and B(D30N/M36I) have been found to favor the combination of protonated D25 
and unprotonated D25’. The other three PRs, B(WT), B(M36V) and B(D30N/M36V), prefer the 
combination of unprotonated D25 and protonated D25’. 
Hydrogen bond criteria. The formation of a hydrogen bond was defined in terms of distance and 
orientation. The combination of donor D, hydrogen H, and acceptor A atoms with a D - H … A 
configuration was regarded as a hydrogen bond when the distance between donor D and acceptor A was 
shorter than 3.5 Å and the angle H-D-A was smaller than 60.0 degrees.  
Calculations of volume and surface area of the binding cavity. 
We employed the Pocket program50 to estimate the vo lume and the surface area of the active site of PR. 
The program is based on the Alpha Shape theory,50 which provides an analytical method for detecting 
pockets in proteins and measuring their volume and surface area. The ligand-binding cavity of HIV-1 PR 
is not completely separated from solvent. However, it should be noted that, in the Pocket program, a 
pocket is  defined as a cavity which is inaccessible to the solvent outside of a protein. If a water molecule 
is  trapped within the pocket, the water molecule cannot escape to the outside of the protein. Hence, we 
can define the ligand-binding cavity as a pocket. Supproting Material Fig. S14 shows the binding pocket 
of HIV-1 PR visualized by MAGE program.51 
Binding free energy calculation. The binding free energy52 was calculated by the following equation: 
∆Gb = ∆Gintele +∆Gintvdw +∆Gsol - T∆S, 
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where ∆Gb  is the binding free energy in solution, ∆Gint
ele  and ∆Gint
vdw  are the electrostatic and van 
der Waals interaction energies between a ligand and a protein, ∆Gsol  is the solvation energy, and 
−T∆S is the contribution of conformational entropy to the binding. In this study, assuming that the 
contribution of conformational entropy to the change in ∆Gb  is  negligible among mutants,53 we 
disregarded the entropy term in the energy estimation. ∆Gint
ele  and ∆Gint
vdw  were computed using the 
same parameter set as that used in the MD s imulation, and no cutoff was applied for the calculation. 
Solvation energy ∆Gsol  was calculated using the pbsa program. The interior dielectric constant was set 
to 2.049 and the outer dielectric constant was set to 80.0. Furthermore, the contribution of each residue to 
the binding free energy was calculated. The total binding free energy was decomposed into the 
contribution from each individual residue by the MM/GBSA method. The modified GB model developed 
by Onufriev, Bashford, and Case54 was used to calculate the solvation energy term. The MM/GBSA 
results were highly correlated with the MM/PBSA results , as we described previously.34 
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Figure legends 
Fig. 1. a: Structure of HIV-1 PR in complex with NFV. Locations of two catalytic aspartates, the 30th and 
the 36th residues, and NFV are shown in ball and stick representations. The amino acid sequence of 
subtype B wild-type (WT) HIV-1 PR (HXB2) and that of M36I mutant are shown under the structure. b: 
Chemical structure of NFV. 
Fig. 2. Distance between the 30th residue of PR and NFV. Red and green solid lines correspond to the 
distance between N of the 30th residue and O1 atom of NFV and that between O of the 30th residue and 
O1 atom of NFV, respectively. Blue solid lines of B(WT), B(M36I), and B(M36V) show the distance 
between OD1/OD2 of D30 and O1 atom of NFV, while those of B(D30N), B(D30N/M36I), and 
B(D30N/M36V) are the distance between OD1/ND2 of N30 and O1 atom of NFV. 
Fig. 3. 3D plot of RMSD of the average structure of each model from that of B(WT). PR is shown in 
colored tube representations. Color indicates the magnitude of RMSD shown in the bottom bar. Each 
model was fitted to B(WT) using the coordinates of main chain atoms N, Ca, and C of PR. The 
superimposed gray tubes represent the average structure of B(WT). 
Fig. 4. Interactions of the 36th residues with L33 and with V77. The average structure of B(WT) was 
superimposed onto that of B(M36I) using the coordinates of N, Cα, and C atoms. The superimposed 
structure of B(WT) was shown in gray sticks and cartoons representation. The orange arrow indicated the 
locations of the 80’s loop, where a prominent change of conformation occurred by M36I. 
Fig. 5. Positional shift of each residue measured from the center of the binding cavity in the average 
coordinate of WT PR. Negative values ind icate contraction of distances measured from the center of the 
cavity, and positive values indicate elongation of the distances. Bottom black lines represent the locations 
of the active site residues. 
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Table
 2 
Table 1. Hydrogen bond networks of NFV with D30 or N30 in PR. 
Donor Acceptor %a Donor Acceptor % 
WT D30N 
N D30 O1b NFV 30.7      
O1 NFV OD1/OD2 D30 31.6      
O1 NFV O D30 42.9      
          
M36I D30N/M36I 
O1 NFV OD2 D30 95.3 O1 NFV O N30 57.1 
          
M36V D30N/M36V 
N D30 O1 NFV 18.0 N N30 O1 NFV 24.9 
O1 NFV OD1/OD2 D30 46.1      
O1 NFV O D30 35.9 O1 NFV O N30 34.7 
          
a  Occupancy of hydrogen bonds during the 2.0-3.0 ns MD simulation. 
b  The atom names of NFV are shown in Fig. 1. 
 
 3 
Table 2. Volume and surface area of the binding cavity in each model. 
 WT M36I M36V D30N D30N 
/M36I 
D30N 
/M36V 
Volume 
 (Å3) 
375 
(±43)a 
345 
(±36) 
365 
(±43) 
403 
(±53) 
419 
(±53) 
375 
(±47) 
Surface 
Area (Å2) 
490 
(±43) 
471 
(±35) 
469 
(±47) 
508 
(±40) 
506 
(±54) 
484 
(±48) 
a The standard deviations were written in the parentheses. 
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Table 3.  Binding free energy of each model. 
 ∆Gint
ele  
(kcal/mo l) 
∆Gint
vdw  
(kcal/mol) 
∆Gsol  
(kcal/mol) 
∆Gb a 
(kcal/mol) 
∆∆Gb
  
(kcal/mol) 
IC50 b 
(nM) 
WT -12.5±1.4 -71.8±3.8 15.1±1.4 -69.2±3.7 - 1.2±0.2 
M36I -11.8±1.2 -73.3±3.7 15.4±1.1 -69.7±3.5 -0.5 0.9±0.1 
M36V -13.2±1.5 -72.1±3.8 16.5±1.3 -68.8±3.6 0.4 ND c 
D30N -6.9±1.2 -70.5±4.1 10.9±0.9 -66.5±3.9 2.7 6.8±0.9 
D30N/M36I -8.1±1.2 -66.8±3.6 9.8±1.1 -65.0±3.5 4.2 6.0±1.0 
D30N/M36V -10.8±1.2 -72.8±3.9 13.3±1.0 -70.3±4.0 -1.1 ND 
a  T∆S is not included. 
b  Reference from the report by Clemente et al.35  
c ND denotes no data. 
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